Abstract
Introduction
sections were examined for cell size and morphology by microscopy. Data presented are 127 representative of 1-4 mice per strain.
128
In vivo titan cell analysis 129 For a subset of infected mice, lungs were lavaged three times with 1.5 ml sterile PBS using a 20- In vitro titan cell analysis 140 To induce the formation of titan cells in vitro, two previously described methods were used (13, 141 14). For the first method (13), C. neoformans cells from a YPD agar plate were transferred to 10 142 ml YPD broth medium in a T25cm3 flask (TPP, Switzerland), grown at 30°C for 22 h with 143 shaking (150 rpm), washed with sterile double distilled water and cell number enumerated with a 144 hemocytometer. Aliquots of 1 X 10 6 cells in 1 ml of minimal media (15 mM glucose, 10 mM 145 MgSO4, 29.4 mM KH2PO4, 13 mM glycine, 3 μM Vit B1, pH5.5) were transferred into 1.5 ml
146
Eppendorf tubes and incubated in a thermomixer at 30°C with shaking (800 rpm) for 48 hours.
147
For the second method (14), yeast cells were grown overnight at 30°C, 150 rpm in 2 ml YNB 148 without amino acids and supplemented with 2% glucose. Yeast cells from the overnight culture were washed twice with sterile PBS, cell number enumerated with a hemocytometer and 150 resuspended in 0.5 ml PBS supplemented with fetal calf serum (FCS, ThermoFisher Scientific) 151 to a final concentration of 1 X 10 3 cells/ml in each well of a 24 well plate. The plates were then 152 incubated at 37°C 5% CO2 for 48 h. After incubation, cell morphology was analyzed by 153 microscopy (AxioImager, Carl Zeiss, Inc.). Cell body diameter was measured as described 154 above. For in vitro titan cell analysis data presented are from 2 biological replicates per strain 155 with 300 cells counted for each replicate.
156
Capsule formation
157
Capsule formation was analyzed from C. neoformans cells generated from (a) in vitro titan cell 
168

Drug resistance assays
169
Drug resistance assays were as described previously (15). Briefly, a microdilution assay was 170 performed according to CLSI guidelines using 2.5 × 10 3 CFU/ml. 
267
We next compared the death/survival of patients and mice infected with the same
268
Cryptococcus strain ( Figure 5 and Table 3 ). All but two of the isolates associated with early 269 mortality in humans showed high virulence in mice ( Figure 5A ). Strains SACl010 and UgCl552 had low virulence in mice but had an early mortality in humans. 
280
All strains associated with late mortality or survival in human patients showed reduced 281 virulence in mice ( Figure 5 and and high virulence strains (Supplemental Figure 4 ).
332
We next compared the susceptibility of the clinical strains to the antifungal drugs 333 fluconazole and amphotericin B, which were used to treat the CM-patients in our cohort. The in 334 vitro susceptibility to the antifungal drugs fluconazole and amphotericin B was not associated 335 with strain virulence (Supplemental Table 2 ). Next, we analyzed the levels of heteroresistance to 336 fluconazole, a factor that was previously associated to C. neoformans virulence (24) showed heteroresistance at 32 μg/ml (Table 4 ). In addition, high virulence strains grew better in 344 the presence of cell wall stressors compared to two of the three low virulence, SACl010 and 345 UgCl552 (Table 4) . However, the low virulence strain UgCl223 did not show any growth defect 346 in any of the tested conditions ( "-" No growth observed, "+" number of dilutions that grew on agar media by spotting assay Progression to severe morbidity was monitored for 160 days, and mice were sacrificed at 160 days or when end point criteria were reached. Lungs (A), spleen (B) and brain (C) were harvested, homogenized and serial dilutions were plated on agar plates to determine tissue fungal burdens. and resuspended in minimal media at a final concentration of 1 x 10 6 cells/ml and incubated at 30°C with shaking (800rpm) in a thermomixer for 48 hours. C)
Capsule induction in PBS and serum: yeast cells were grown overnight in YNB, washed and then transferred into PBS supplemented with FCS and incubated at 37°C, 5% CO2 for 48 hours. After incubation, yeast cells were fixed with 3.7% formaldehyde and observed under the microscope. The capsule width was defined as the difference between the diameter of the whole yeast cell (cell body and capsule) and the cell body diameter (no capsule) divided by 2. DMEM: Dulbecco's
